As the MEK inhibitor U0126 blocked FTD‐induced AKT/ERK/STAT3, EGFR T669, and S1046/1047 phosphorylation to a similar extent as panitumumab, the effect of cotreatment with FTD and the MEK inhibitors U0126 or trametinib on cell proliferation was evaluated. Here, MAP2K7 is linked to frontotemporal dementia.